This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2022
ESMO 2022 Testicular and Penile Cancer
ESMO 2022
Prostate Cancer
Bladder Cancer
Testicular and Penile Cancer
Press Releases
Kidney Cancer
ESMO 2022 Testicular and Penile Cancer
Viewing 141-160 of 11745 articles
ESMO 2024: ctDNA Clearance with Neoadjuvant Durvalumab + Tremelimumab + Enfortumab Vedotin for Cisplatin-Ineligible MIBC from the Safety Run-in Cohort of the Phase 3 VOLGA Trial
ESMO 2024: Non-Clear Cell RCC
ESMO 2024: CARE1 Pragmatic Clinical Trial - First Line Randomised Study Platform to Optimize Treatment in Patients with Metastatic Renal Cell Carcinoma
ESMO 2024: Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma vs Observation: Extended Follow-up DFS Results and Metastatic Disease Recurrence Distribution
ESMO 2024: Invited Discussant: Improving Outcomes of Localized Urothelial Cancer
ESMO 2024: T Cell Engagers in Prostate Cancer
ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer
ESMO 2024: Outcomes with Novel Combinations in Non-Clear Cell RCC: ORACLE Study
ESMO 2024: Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial – 3 Year Update
ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients
ESMO 2024: Does Lower Serum Testosterone Predict Metastases-Free Survival in nmCRPC Patients Treated with Novel Antiandrogens? a Post-Hoc Analysis of SPARTAN and ARAMIS
ESMO 2024: Determination of Tumor PSMA Expression in Prostate Cancer from Blood Using a Novel Epigenomic Liquid Biopsy Platform
ESMO 2024: Surveillance/minimal Intervention for Good Risk Disease
ESMO 2024: B7-H3 as Therapeutic Target for Prostate Cancer
ESMO 2024: Assessment of the Utility of CT Scans in the Long-Term Follow-up of Metastatic Non-Seminomatous Germ Cell Tumors: The Late CT Study
ESMO 2024: TAMARACK: Randomized Phase 2 Trial of the B7-H3 Targeting Antibody Drug Conjugate Vobramitamab
ESMO 2024: SAABR: Single Arm Phase II Study of Androgen Receptor Pathway Inhibitor + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy to the Prostate in Men with De Novo Hormone-sensitive Metastatic Prostate Cancer
ESMO 2024: Association of PD-L1 Expression with Clinical Response to TAR-200 in the Phase 2b SunRISe-1 Trial
ESMO 2024: Intensification of Systemic Treatment for Poor Risk Disease
ESMO 2024: The STAMPEDE2 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Metastatic Prostate Cancer Starting ADT
3
4
5
6
7
8
9
10
11
12
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
